Alejandra Mørk

Board Member and Strategic Drug Development Advisor

For more than 30 years, Alejandra Mørk has worked with drug development. She has worked on strategic levels for development portfolios in pharma and for biotech, and in tactical and operations roles in Project Management, Clinical Development and Regulatory Affairs. Her experience covers interaction with US and EU regulatory agencies for a broad range of therapeutic indications and technologies from small molecules to ATMP project. After 18 years in Pharma including overall head for Drug Development in Nycomed, she acquired KLIFO in 2008, developed the company into a well-established consultancy company that was acquired by Gilde Healthcare in 2021.